Resultados de Pesquisa

INGLÊS

Targeting Oncogenic Driver Mutations In Lung Cancer

de Alain Borczuk, Balazs Halmos, Fawzi Abu Rous, Matthew Lee, Shirish Gadgeel e Stephen Liu

23,85€ + 10% EM CARTÃO

DISPONIBILIDADE IMEDIATA
INGLÊS

Egfr-Directed Therapy In Lung Cancer

de Balazs Halmos, Daisuke Shibahara, Daniel B. Costa, So Yeon Kim e Susumu Kobayashi

23,85€ + 10% EM CARTÃO

DISPONIBILIDADE IMEDIATA
INGLÊS

Egfr-Directed Therapy In Lung Cancer

de Balazs Halmos, Daisuke Shibahara, Daniel B. Costa, So Yeon Kim e Susumu Kobayashi

23,85€ + 10% EM CARTÃO

DISPONIBILIDADE IMEDIATA
INGLÊS

Targeting Oncogenic Driver Mutations In Lung Cancer

de Alain Borczuk, Balazs Halmos, Fawzi Abu Rous, Matthew Lee, Shirish Gadgeel e Stephen Liu

23,85€ + 10% EM CARTÃO

DISPONIBILIDADE IMEDIATA

 The recent advances in the field of molecular diagnostic techniques have led to the identification of targetable alterations prompting a paradigm shift in the management of non-small cell lung cancer (NSCLC) and an era of precision oncology. This Element highlights the most clinically relevant oncogenic drivers other than EGFR, their management and current advancements in treatment. It also examines the different challenges in resistance to targeted therapies and diagnostic dilemmas for each oncogenic driver and the future direction of NSCLC management.
INGLÊS

Egfr-Directed Therapy In Lung Cancer

de Balazs (Albert Einstein College Of Medicine, New York) Halmos, Daisuke (Harvard Medical School, Massachusetts) Shibahara, Daniel B. (Harvard Medical School, Massachusetts) Costa, So Yeon (Yale School Of Medicine, Connecticut) Kim e Susumu (Harvard Medical School, Massachusetts) Kobayashi

24,33€ + 10% EM CARTÃO

portes grátis

 This Element describes the structural biology and pathophysiology of EGFR-mutant NSCLC and describes past, current, and future treatment options in different settings. It discusses the biology and recently approved treatment for EGFR-exon 20 insertion mutation and the treatment for the uncommon mutations.
INGLÊS

Targeting Oncogenic Driver Mutations In Lung Cancer

de Alain (Weill Cornell Medicine) Borczuk, Balazs (Montefiore Medical Center And Albert Einstein College Of Medicine) Halmos, Fawzi (Henry Ford Health System) Abu Rous, Matthew (Montefiore Medical Center And Albert Einstein College Of Medicine) Lee, Shirish (Henry Ford Health System) Gadgeel e Stephen (Lombardi Comprehensive Cancer Center, Georgetown University, Washington Dc) Liu

24,33€ + 10% EM CARTÃO

portes grátis

 This Element highlights the most clinically relevant oncogenic drivers other than EGFR, their management and current advancements in treatment. It also examines the different challenges in resistance to targeted therapies and diagnostic dilemmas for each oncogenic driver and the future direction of NSCLC management.
INGLÊS

Therapeutic Targeting Of Ras Mutant Cancers

de Edward C. Stites, Kendra Paskvan e Shumei Kato

23,85€ + 10% EM CARTÃO

DISPONIBILIDADE IMEDIATA
INGLÊS

Therapeutic Targeting Of Ras Mutant Cancers

de Edward C. Stites, Kendra Paskvan e Shumei Kato

23,85€ + 10% EM CARTÃO

DISPONIBILIDADE IMEDIATA

 The KRAS oncogene is believed to be the most common single nucleotide variant oncogene in human cancer. Historically, efforts to target KRAS and the other RAS GTPases have struggled. More recently, efforts have focused on identifying and exploiting features unique to specific oncogenic mutations.
INGLÊS

Therapeutic Targeting Of Ras Mutant Cancers

de Edward C. (Salk Inst Itute For Biological Studies, La Jolla, Ca) Stites, Kendra (Pacific Northwes T University For Health Sciences, Yakima, Wa) Paskvan e Shumei (University Of California, San Diego Moores Cancer Center) Kato

24,33€ + 10% EM CARTÃO

portes grátis

 The KRAS oncogene is believed to be the most common single nucleotide variant oncogene in human cancer. Historically, efforts to target KRAS and the other RAS GTPases have struggled. More recently, efforts have focused on identifying and exploiting features unique to specific oncogenic mutations.
INGLÊS

Personalized Drug Screening For Functional Tumor Profiling

de Hichul Kim, Tatiana Michel, Victoria El-Khoury e Yong-Jun Kwon

23,85€ + 10% EM CARTÃO

DISPONIBILIDADE IMEDIATA
INGLÊS

Personalized Drug Screening For Functional Tumor Profiling

de Hichul Kim, Tatiana Michel, Victoria El-Khoury e Yong-Jun Kwon

23,85€ + 10% EM CARTÃO

DISPONIBILIDADE IMEDIATA
INGLÊS

Personalized Drug Screening For Functional Tumor Profiling

de Hichul Kim, Tatiana Michel, Victoria El-Khoury e Yong-Jun Kwon

24,33€ + 10% EM CARTÃO

portes grátis

 This Element discusses personalized drug screening as a novel patient stratification strategy for the determination of individualized treatment choices in oncology.

NÃO ENCONTROU O QUE PROCURA?

Faça consulta pelos temas do menu.

Consulte os critérios de pesquisa na ajuda .

E por fim, se necessário, utilize a opção procuramos por si .